Td Asset Management Inc Cytom X Therapeutics, Inc. Transaction History

Td Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$6.33 - $9.91 $498,936 - $781,116	-78,821 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$6.6 - $9.0 $520,218 - $709,389	78,821 New	78,821 $609,000
Q4 2019 Feb 11, 2020	SELL	$5.17 - $8.91 $181,890 - $313,471	-35,182 Closed	0 $0
Q3 2019 Nov 07, 2019	SELL	$7.38 - $12.25 $84,132 - $139,650	-11,400 Reduced 24.47%	35,182 $260,000
Q1 2019 May 08, 2019	SELL	$9.5 - $19.16 $132,050 - $266,324	-13,900 Reduced 22.98%	46,582 $501,000
Q4 2018 Feb 01, 2019	SELL	$12.69 - $18.61 $55,836 - $81,884	-4,400 Reduced 6.78%	60,482 $913,000
Q3 2018 Nov 01, 2018	BUY	$18.04 - $26.41 $318,983 - $466,981	17,682 Added 37.46%	64,882 $1.2 Million
Q2 2018 Jul 31, 2018	BUY	$21.38 - $29.68 $79,106 - $109,816	3,700 Added 8.51%	47,200 $1.08 Million
Q1 2018 May 11, 2018	BUY	$21.76 - $34.22 $946,560 - $1.49 Million	43,500 New	43,500 $1.24 Million

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $69.9M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.